The Supreme Court of India condemned forum shopping as an abuse of court process and upheld the validity of drug price fixation notifications issued by the Central Government under the Drugs (Prices Control) Order, 1995. The division bench ruled that pharmaceutical manufacturers cannot file parallel writ petitions across multiple High Courts to obtain conflicting interim reliefs.
Litigation History and Drug Price Regulation Under DPCO 1995
In Union of India and Others versus M/S. Cipla Limited and Another (Civil Appeal Number 329 of 2005 with Civil Appeal Number 4005 of 2004), the Supreme Court heard appeals against a judgment of the Allahabad High Court. The underlying dispute arose from notifications issued by the Central Government fixing ceiling prices and retail prices for essential bulk drugs and formulations under the Drugs Prices Control Order DPCO 1995.
The respondent pharmaceutical companies challenged these price notifications, arguing that the National Pharmaceutical Pricing Authority and the Ministry of Chemicals and Fertilizers failed to apply relevant costing norms and procedural guidelines while determining maximum sale prices. The manufacturers asserted that input raw materials, conversion costs, packaging expenses, and local transportation levies had escalated, making the notified prices commercially unfeasible. The Allahabad High Court struck down the notifications on the ground of non-application of mind by the executive authorities.
The Central Government appealed to the Supreme Court, contending that price fixation is a legislative and policy function delegated to specialized expert committees. Furthermore, the Union brought to the notice of the court that multiple pharmaceutical manufacturers had instituted concurrent writ petitions challenging identical notifications across the High Courts of Allahabad, Bombay, Delhi, and Karnataka, obtaining inconsistent interim orders that stalled statutory price enforcement nationwide.
The Doctrine of Forum Shopping and Abuse of Court Process
A division bench comprising Justice Madan B. Lokur and Justice R.K. Agrawal delivered a landmark pronouncement on the definition and consequences of forum shopping Supreme Court India jurisprudence. The bench defined forum shopping as a disreputable practice where a litigant attempts to find a court or judge that may view their claim favorably, often by approaching one court after failing in another, or by instituting simultaneous proceedings in different forums on the same cause of action.
The court observed that such manipulative practices represent an abuse of court process multiple High Courts strategy designed to exploit jurisdictional boundaries. Litigants who suppress the pendency of similar petitions in other High Courts or seek divergent interim protections waste judicial time and cause administrative chaos in regulatory enforcement. Applying the doctrine of forum shopping Supreme Court India standards, the bench stated that such conduct degrades the authority of the judiciary and creates conflicting jurisprudence on national economic policies.
The Supreme Court held that courts must discourage opportunistic forum shopping by refusing discretionary equitable relief under Article 226 of the Constitution to parties who conceal parallel litigation. The bench reiterated that judicial decorum and comity demand strict adherence to territorial propriety, preventing corporate litigants from shopping for hospitable forums and requiring full disclosure of all related filings.
Limits of Judicial Review in Drug Price Fixation and Expert Policy
On the substantive regulatory challenge, the bench scrutinized the scope of drug price fixation judicial review under administrative law. The court affirmed that price fixation is essentially a legislative function. Courts exercising judicial review do not sit as appellate bodies over expert pricing committees or substitute their own economic formulas for administrative calculations.
Justice Lokur explained that unless a price notification is demonstrated to be ultra vires the parent statute, blatantly arbitrary, or discriminatory under Article 14 of the Constitution, constitutional courts will not interfere with price ceilings fixed for life-saving medicines. The government retains broad policy discretion to regulate pharmaceutical prices to make essential healthcare affordable for the general public.
The bench observed that the material placed before the pricing authorities demonstrated adequate consideration of production costs, packaging materials, and manufacturer margins. The Allahabad High Court erred in undertaking an overly pedantic review of technical costing components that belonged strictly to the domain of regulatory experts. When the executive acts within statutory parameters, judicial restraint is the governing principle.
The court addressed the procedural impropriety of introducing fresh calculations and technical data directly before the appellate court. Litigants cannot withhold vital factual data from the High Court and subsequently tender voluminous technical appendices at the special leave stage, as doing so deprives lower courts of relevant facts and disrupts the appellate hierarchy.
Institutional Accountability and Public Access to Affordable Medicine
The judgment establishes vital safeguards for public health governance. Pharmaceutical price control serves a paramount constitutional objective: protecting vulnerable patients from prohibitive healthcare expenses. Allowing corporate entities to delay essential drug pricing through strategic litigation undermines socio-economic justice and distorts fair market practices.
Public advocacy for transparent governance and civic accountability, supported by initiatives outlined in Our Campaign, relies on clear regulatory compliance. When courts enforce procedural discipline against forum shopping, regulatory authorities can implement welfare policies without artificial disruption, strengthening universal Access to Justice and equitable healthcare delivery across India.
By setting aside the Allahabad High Court decision and upholding the government notifications, the Supreme Court reaffirmed the supremacy of public interest over procedural manipulation in regulatory litigation.
Summary of Core Principles Established by the Supreme Court
- Forum shopping is an abuse of judicial process that disentitles litigants from claiming equitable relief.
- Price fixation under the Drugs (Prices Control) Order, 1995 is a legislative function subject to limited judicial review.
- Courts will not substitute their judgment for the economic findings of specialized pricing authorities.
- Litigants have a positive obligation to disclose parallel proceedings instituted before other High Courts.
- Submitting fresh evidentiary documents directly before the Supreme Court without prior presentation in High Court is strongly discouraged.